DOI: 10.26155/vet.zoo.bio.202011004
UDC 636.1

Authors

Rozhdestvenskaya T. N.,
Doctor of Veterinary Sciences, Director for Science, Scientific-Production Enterprise “AVIVAC”, Saint-Petersburg, Russian Federation Head of the Laboratory of Bird Diseases. Federal Scientific Center – All-Russian Scientific Research Institute of Experimental Veterinary Medicine named after K. I. Scriabin and Ya. R. Kovalenko of the Russian Academy of Sciences, Moscow, Russian Federation
Pankratov S. V.
Candidate of Veterinary Sciences, Deputy Director for Quality, Scientific-Production Enterprise “AVIVAC”, Saint-Petersburg, Russian Federation
Sapegina Е. V.
Serologist, Deputy Director of Diagnostic Center, Scientific-Production Enterprise “AVIVAC”, Saint-Petersburg, Russian Federation
Tomina Е.V.
Head of Quality Control Department, Scientific- Production Enterprise “AVIVAC” Saint-Petersburg, Russian Federation

Abstract

This article presents the results of testing vaccines against avian hemophilia based on inactivated antigens of Avibacterium paragallinarum serotypes “A”, “B” and “C” using GOA adjuvant and Montanide ISA 71 R VG oil adjuvant (manufactured by SEPPIC, France).
The relevance of this work is dictated by the need to research the most immunogenic and less reactogenic adjuvants for inactivated vaccines against avian hemophilia. Successful prevention of infectious diseases should be based on an integrated approach and provide not only for the implementation of veterinary and sanitary measures, full compliance with poultry growing technologies and the use of effective therapeutic drugs, but also for the use of modern and safe means of specific prophylaxis (vaccine prophylaxis).
hemophiliа made with the use of GOA adjuvant and Montanide ISA-71 R VG adjuvant completely correspond to the main quality criteria of preparation of this class – having no reactogenicity and have sufficient protective properties to protect birds from infection with field pathogens of hemophilia.

Keywords

Avibacterium paragallinarum, avian hemophilia, bacterial diseases, mixed infection, adjuvants, inactivated vaccines, vaccine prophylaxis, reactogenicity, protective properties.